Heterogeneous neuropathological findings in Parkinson’s disease with mild cognitive impairment
Parkinson’s disease (PD) patients often develop mild cognitive impairment (PD-MCI) and dementia (PDD) [5, 8]. The pathologic substrate for PDD appears to be heterogeneous and includes Lewy bodies, Alzheimer’s disease (AD) pathology, and cerebrovascular disease [6, 7, 9, 10]. Neuropathological changes in PD-MCI have not been described.
We present eight PD-MCI cases clinically and neuropathologically characterized as previously described [2, 4, 5]. The cognitive battery assessed five domains (memory, frontal/executive, language, attention, and visuospatial) using previously described PD-MCI criteria . Lewy bodies were staged using the Unified Lewy Body Staging System  while AD and cerebrovascular pathology were assessed using standardized procedures .
KeywordsMild Cognitive Impairment Lewy Body Neuritic Plaque Lewy Body Pathology Cerebrovascular Pathology
This work was funded by the Arizona Biomedical Research Commission (contracts 4001, 05-901, 0011, and 1001), the Michael J. Fox Foundation for Parkinson’s Research (Prescott Family Initiative), the Arizona Department of Health Services (contract 211002), and the National Institute on Aging (P30 AG19610).
Conflict of interest
The authors declare that they have no conflicts of interest.
- 2.Adler CH, Hentz JG, Joyce JN, Beach T, Caviness JN (2002) Motor impairment in normal aging, clinically possible Parkinson’s disease, and clinically probable Parkinson’s disease: longitudinal evaluation of a cohort of prospective brain donors. Parkinsonism Relat Disord 9:103–110CrossRefPubMedGoogle Scholar